A carregar...
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
BACKGROUND: In older patients with overactive bladder (OAB), mirabegron, a β(3)-adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk–benefit profile. OBJECTIVES: Our objective was to further examine the safety and tolerability of mirabegron versus placebo treatm...
Na minha lista:
| Publicado no: | Drugs Aging |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473960/ https://ncbi.nlm.nih.gov/pubmed/32725584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40266-020-00783-w |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|